Arcutis Biotherapeutics, Inc
Price
FilingsNewest: 13G, Stake over 5%, passiveAug 14 →InsidersNo open-market buys. 10 insiders sold $13.9M, 60 of 63 sales on a 10b5-1 plan.→HoldersMontanova Capital 9.9%BlackRock 8.4%Frazier Life Sciences 7.9%→PeersClosest companies: VRDN, ADCT, NUVB→
From the filings
Figures
- Revenue
- $462.0Mlast 12 months
- Net income
- $28.5Mlast 12 months
- Operating cash flow
- $27.0Mlast 12 months
- Cash and equivalents
- $34.1Mat the last balance sheet
- Total debt
- $108.9Mat the last balance sheet
- Shares outstanding
- 125.6M shareson issue